132.66
前日終値:
$137.36
開ける:
$137.06
24時間の取引高:
8.51M
Relative Volume:
1.51
時価総額:
$230.08B
収益:
$41.95B
当期純損益:
$13.40B
株価収益率:
17.34
EPS:
7.65
ネットキャッシュフロー:
$6.35B
1週間 パフォーマンス:
-3.58%
1か月 パフォーマンス:
+0.93%
6か月 パフォーマンス:
+13.77%
1年 パフォーマンス:
+10.38%
Abbott Laboratories Stock (ABT) Company Profile
名前
Abbott Laboratories
セクター
電話
(224) 667-6100
住所
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
ABT を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
ABT
Abbott Laboratories
|
132.66 | 230.08B | 41.95B | 13.40B | 6.35B | 7.65 |
![]()
BSX
Boston Scientific Corp
|
95.52 | 140.97B | 16.75B | 1.85B | 2.37B | 1.25 |
![]()
SYK
Stryker Corp
|
365.29 | 139.39B | 22.60B | 2.99B | 3.49B | 7.76 |
![]()
MDT
Medtronic Plc
|
93.28 | 119.61B | 33.20B | 4.26B | 5.47B | 3.29 |
![]()
EW
Edwards Lifesciences Corp
|
68.39 | 40.21B | 5.72B | 4.17B | 259.90M | 6.97 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-10-08 | 開始されました | Oppenheimer | Outperform |
2024-09-19 | 開始されました | Piper Sandler | Overweight |
2024-07-30 | ダウングレード | Edward Jones | Buy → Hold |
2024-05-30 | 開始されました | Goldman | Buy |
2023-07-21 | アップグレード | Wolfe Research | Underperform → Peer Perform |
2023-05-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2023-04-20 | 繰り返されました | Barclays | Overweight |
2023-04-20 | 繰り返されました | Bernstein | Outperform |
2023-04-20 | 繰り返されました | JP Morgan | Overweight |
2023-04-20 | 繰り返されました | Raymond James | Outperform |
2023-04-20 | 繰り返されました | UBS | Buy |
2023-04-20 | 繰り返されました | Wolfe Research | Underperform |
2023-03-29 | 開始されました | UBS | Buy |
2022-10-26 | 開始されました | Mizuho | Neutral |
2022-10-18 | 開始されました | Barclays | Overweight |
2022-10-12 | 開始されました | Jefferies | Hold |
2022-07-06 | 開始されました | Wolfe Research | Underperform |
2022-03-02 | 再開されました | BofA Securities | Buy |
2022-01-27 | 繰り返されました | Credit Suisse | Outperform |
2022-01-27 | 繰り返されました | Morgan Stanley | Overweight |
2022-01-27 | 繰り返されました | Raymond James | Outperform |
2022-01-27 | 繰り返されました | UBS | Buy |
2021-12-10 | 開始されました | RBC Capital Mkts | Outperform |
2021-10-27 | アップグレード | Atlantic Equities | Neutral → Overweight |
2021-10-14 | 開始されました | Redburn | Neutral |
2021-05-25 | 開始されました | Barclays | Overweight |
2021-04-15 | 開始されました | Atlantic Equities | Neutral |
2021-01-28 | アップグレード | BTIG Research | Neutral → Buy |
2020-09-11 | 開始されました | Wolfe Research | Outperform |
2020-06-01 | ダウングレード | Goldman | Neutral → Sell |
2020-03-05 | 開始されました | Citigroup | Buy |
2020-02-13 | 開始されました | Goldman | Neutral |
2020-02-06 | 再開されました | BTIG Research | Neutral |
2020-01-02 | ダウングレード | Guggenheim | Buy → Neutral |
2019-06-13 | 繰り返されました | BofA/Merrill | Buy |
2019-02-07 | 繰り返されました | BofA/Merrill | Buy |
2019-01-02 | ダウングレード | Citigroup | Neutral → Sell |
2018-11-30 | アップグレード | Goldman | Neutral → Buy |
2018-10-16 | 開始されました | Barclays | Overweight |
2018-06-27 | 開始されました | Bernstein | Outperform |
2018-01-30 | 繰り返されました | Citigroup | Neutral |
2018-01-25 | 繰り返されました | Stifel | Buy |
2018-01-25 | アップグレード | William Blair | Mkt Perform → Outperform |
2018-01-03 | 開始されました | Evercore ISI | Outperform |
2018-01-02 | アップグレード | JP Morgan | Neutral → Overweight |
2018-01-02 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2017-10-19 | 繰り返されました | RBC Capital Mkts | Outperform |
2017-10-19 | 繰り返されました | Stifel | Buy |
すべてを表示
Abbott Laboratories (ABT) 最新ニュース
OTC Consumer Health Market Positioned for Accelerated Growth with Johnson&Johnson, Abbott Laboratories, - EIN News
Breast Cancer Diagnostics Market Set for 6.9% CAGR Growth, projected to Hit USD 12.45 Billion by 2035 - GlobeNewswire Inc.
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know - Nasdaq
Neurological Biomarkers: Global Market Review 2020-2024 and - GlobeNewswire
Abbott Laboratories (NYSE:ABT) Given New $150.00 Price Target at Bank of America - Defense World
Abbott Laboratories Options Trading: A Deep Dive into Market Sentiment - Benzinga
BofA Raises Price Target on Abbott Laboratories to $150 From $133 -March 10, 2025 at 10:06 am EDT - Marketscreener.com
Electroceutical Devices Market Projected To Witness Substantial Growth, 2025-2032: Medtronic plc, Abbott - EIN News
Abbott Laboratories Stock Analysis: Short-Term Gains vs. Long-Term ChallengesNews and Statistics - IndexBox, Inc.
3 Reasons to Avoid ABT and 1 Stock to Buy Instead - Yahoo Finance
Cancer Diagnostics Market Top PlayersGE Healthcare, Abbott - openPR
Shedd Aquarium receives $10 million pledge from Abbott - Philanthropy News Digest
ServiceNow, Abbott, Chipotle, Archer, T-Mobile Stock Shakeup! - TipRanks
Estimating The Fair Value Of Abbott Laboratories (NYSE:ABT) - Yahoo Finance
Abbott Labs sued for alleged ADA, human rights and whistleblower protection violations - Press Herald
Top Executive Cashes In on Abbott Laboratories Stock! - TipRanks
Abbott Laboratories EVP Lisa Earnhardt sells $12.2m in stock - Investing.com
Japan In-Vitro Diagnostics Market Forecast Report and - GlobeNewswire
Strong Earnings Lift Abbott Laboratories Shares - FX Empire
Citigroup Forecasts Strong Price Appreciation for Abbott Laboratories (NYSE:ABT) Stock - Defense World
Invest with Confidence: Intrinsic Value Unveiled of Abbott Labor - GuruFocus.com
Insider Sell: Andrea Wainer Sells Shares of Abbott Laboratories (ABT) - GuruFocus.com
Cadrenal and Abbott sign agreement for LVAD trial of tecarfarin - Medical Device Network
Padeiatricans’ summit sponsored by infant formula maker in violation of law - The Times of India
Bioelectric Medicine Market Top Companies Study- Abbott - openPR
Abbott Laboratories (NYSE:ABT) Hits New 12-Month High on Analyst Upgrade - Defense World
Drug Testing Market Is Booming Worldwide 2025-2032 | Abbott - openPR
Abbott Laboratories VP John McCoy Jr. sells $77,651 in stock By Investing.com - Investing.com South Africa
Abbott Laboratories SVP Eric Shroff sells $77,651 in stock - Investing.com
Abbott Laboratories retired EVP Andrea Wainer sells $131,123 in stock - Investing.com
Abbott Laboratories EVP Louis Morrone sells $153,506 in shares - Investing.com India
Abbott Laboratories EVP Mary Moreland sells shares worth $109,292 - Investing.com
Abbott Laboratories VP John McCoy Jr. sells $77,651 in stock - Investing.com
Healthcare Stocks Fall, Led Lower by SuppliersHealthcare Roundup -March 04, 2025 at 05:07 pm EST - Marketscreener.com
IRS Asks To Toss Abbott Labs' FOIA Action For Tax Records - Law360
Cognitive Enhancement Wearable Technology Patent Landscape - GlobeNewswire
Where Abbott Laboratories Stands With Analysts - Benzinga
Abbott Laboratories (NYSE:ABT) Partners With Cadrenal Therapeutics For TECH-LVAD Trial In Growing US$2B LVAD Market - Simply Wall St
Here's why Jim Cramer disagrees with latest Wall Street call on Abbott Labs - CNBC
He Fought Claims of Harm From Infant Formula. Now He Regulates It. - The New York Times
Patent Foramen Ovale Closure Devices Market is Booming - openPR
Cognitive Enhancement Wearable Technology Patent Landscape Report, 2017-2023 & 2024-2032 with Patent Profiles of Abbott Laboratories, IBM, Nestec, University of California, and Koninkl Philips Electronics - Yahoo Finance
Cadrenal partners with Abbott for heart device trial - Investing.com India
Can Cadrenal's Tecarfarin Revolutionize Treatment for HeartMate 3 LVAD Patients? - StockTitan
Drug Eluting Stents Market Is Booming So Rapidly: Abbott Laboratories, Boston Scientific Corporation - openPR
Is Abbott Laboratories' (NYSE:ABT) Stock's Recent Performance Being Led By Its Attractive Financial Prospects? - Yahoo Finance
Goldman Sachs Adjusts Price Target on Abbott Laboratories to $154 From $138, Keeps Buy Rating - Marketscreener.com
Gastritis Treatment Market Deep Research 2025-2032 | Abbott Laboratories, AstraZeneca PLC - openPR
A secretary turned $180 into $7.2 million by holding her employer's stock for 75 years - AOL
Is Abbott Laboratories Stock Outperforming the Dow? - Nasdaq
Abbott Laboratories Reaches Analyst Target Price - Nasdaq
Abbott Laboratories (ABT) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):